Medical devices, healthcare technology and the business of care
PMA SUPPLEMENT · P150031/S089

Vercise Genus Deep Brain Stimulation (DBS) Systems

Boston Scientific Corp · Decision date Dec 10, 2025

FDA DECISIONP150031/S089

What did the FDA approve?

FDA records P150031/S089 as a supplement to PMA P150031, with the supplement type “Real-Time Process”. The recorded decision is approval, dated Dec 10, 2025.

FDA approval order statement

approval for the extension of shelf-life from 6 months to 15 months for the Hydrogen Silsesquioxane material utilized in the insulation layer production of a component within the printed circuit board assembly of Implantable Pulse Generator (IPG) and of External Trial Stimulator (ETS) Kits in the WaveWriter Alpha Prime Spinal Cord Stimulation and Vercise Genus Deep Brain Stimulation Systems. The component, manufactured by a third-party supplier, is not patient-contacting and is fully encapsulated within the IPG and ETS.
Regulatory pathway
PMA supplement
Supplement type
Real-Time Process
Clinical specialty
Neurology
Decision date
Dec 10, 2025
FDA change category
Change Design/Components/Specifications/Material

FDA source record

Regulatory record facts

Identifier
P150031/S089
Regulatory pathway
PMA supplement
Product code
NHL
Decision code
APPR
Decision date
Dec 10, 2025
Source update
Nov 9, 2026
Original record
Open FDA source record

About this medical device

FDA device category: Stimulator, electrical, implanted, for parkinsonian symptoms.

Product code
NHL
FDA device class
3

For the original device and its historical approval scope, see PMA P150031. Subsequent supplements may change the device or its indications.

FDA decision timeline

  1. P150031 · Original PMA

    VERCISE DEEP BRAIN STIMULATION (DBS)SYSTEM

  2. P150031/S087 · Related supplement

    Vercise Deep Brain Stimulation (DBS) Systems

  3. P150031/S089 received

    Application receipt date recorded by FDA.

  4. P150031/S089 · FDA decision

    Real-Time Process

  5. P150031/S090 · Related supplement

    Vercise Deep Brain Stimulation (DBS) Systems

  6. P150031/S091 · Related supplement

    Vercise Deep Brain Stimulation (DBS) Systems

  7. P150031/S093 · Related supplement

    (Vercise Deep Brain Stimulation (DBS) Systems)

  8. P150031/S094 · Related supplement

    Vercise Deep Brain Stimulation (DBS) Systems

  9. P150031/S092 · Related supplement

    Deep Brain Stimulation (DBS) Systems

  10. P150031/S095 · Related supplement

    Vercise Deep Brain Stimulation (DBS) Systems

  11. P150031/S096 · Related supplement

    Vercise Deep Brain Stimulation (DBS) Systems

  12. P150031/S097 · Related supplement

    Vercise Deep Brain Stimulation (DBS) Systems

  13. P150031/S084 · Related supplement

    VERCISE DEEP BRAIN STIMULATION (DBS) SYSTEM

  14. P150031/S098 · Related supplement

    Vercise Genus DBS Systems; Vercise Gevia DBS Systems

  15. P150031/S102 · Related supplement

    Vercise Deep Brain Stimulation (DBS) Systems

Timeline entries are records held by MedtechLedger for P150031. View FDA’s full supplement list.

Related devices and submissions

Same PMA: P150031

Product / regulatory recordCompanyPathwayDecision dateSource
Boston Scientific CorpPMA approvalDec 8, 2017FDA
Boston Scientific CorpPMA supplementSep 19, 2025FDA
Boston Scientific CorpPMA supplementDec 17, 2025FDA
Boston Scientific CorpPMA supplementJan 22, 2026FDA
Boston Scientific CorpPMA supplementMay 13, 2026FDA
Boston Scientific CorpPMA supplementMay 18, 2026FDA
Boston Scientific CorpPMA supplementMay 28, 2026FDA
Boston Scientific CorpPMA supplementJul 10, 2026FDA
Boston Scientific CorpPMA supplementJul 16, 2026FDA
Boston Scientific CorpPMA supplementAug 10, 2026FDA
Boston Scientific CorpPMA supplementSep 13, 2026FDA
Boston Scientific CorpPMA supplementSep 22, 2026FDA
Boston Scientific CorpPMA supplementOct 15, 2026FDA
Boston Scientific CorpPMA supplementOct 30, 2026FDA

Explore the linked device profile

Regulatory context

A PMA supplement records a change to a device with an existing premarket approval. The supplement’s approval applies to the change described in that submission.

FDA describes the real-time supplement process as a review route for minor changes to a device, including certain design, software, sterilization or labeling changes.

Read our guide to FDA clearance and approval · FDA’s explanation of this pathway

Manufacturer intelligence

Boston Scientific Corp

Headquarters
Not reported
FDA applicant address
25155 Rye Canyon Loop, Valencia, CA, 91355

Sources and methodology

FDA fields and approval-order wording are presented as source information. MedtechLedger explanations are identified separately and describe the scope of the recorded decision. Indications from an original PMA are historical unless confirmed against subsequent labeling and supplements.

How we use FDA records